PET-MF

1 clinical trials · Condition

Record	Firm	Date
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) (NCT06343805)	Ajax Therapeutics, Inc.	2024-10-23

Every clearance here is in the API, with alerts when new ones post.